The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Subscribe To Our Newsletter & Stay Updated
